about
Influence of HIV and HCV on T cell antigen presentation and challenges in the development of vaccinesEvidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus InfectionTracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus InfectionFull-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute InfectionInfluence of host resistance on viral adaptation: hepatitis C virus as a case studyIL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyAbacavir-reactive memory T cells are present in drug naïve individualsThe broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine designAdaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs.Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions.Influence of human leukocyte antigen (HLA) alleles and killer cell immunoglobulin-like receptors (KIR) types on heparin-induced thrombocytopenia (HIT).Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity.Genetic variations in IL28B and allergic disease in children.Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins.Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreakHepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Host genetic determinants of spontaneous hepatitis C clearance.Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection.Fibrosing mediastinitis complicating prior histoplasmosis is associated with human leukocyte antigen DQB1*04:02 - a case control study.Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus InfectionViral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease.Anti-hepatitis C virus T-cell immunity in the context of multiple exposures to the virus.Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses.Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotypeHelicobacter pylori adaptation in vivo in response to a high-salt diet.Comparison of HLA allelic imputation programs.Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system.Extensive HLA-driven viral diversity following a narrow-source HIV-1 outbreak in rural China.A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics.Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope.The interferon family as biomarkers of disease: renaissance of the innate immune system.IFN-λ and IgE-mediated allergic disease: a potential future role?Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening.
P50
Q26999264-AF999099-0664-412E-B07F-21A00C039FE6Q27477614-C7775C2F-92B2-450F-8AAE-EB7F3B35FACCQ27480870-D039846A-A016-45F1-A9E8-2A73EBE877F4Q27490315-E6109EC9-17BC-4145-9A54-733C066E3507Q28087595-44EC141E-99F8-4F70-B223-344C0BE9021FQ28477057-01B75DBF-DEEC-4D9F-A1FC-DE991AF70992Q28543405-11AF5F1F-EFB3-4BF8-8022-36323F693D4AQ28602408-158AB6EC-2177-4C26-98D5-6B603A1CD3F9Q30386701-64876692-EBE3-4F2A-92F0-7D47CEF7A115Q30407004-C5CA90DC-15D9-46AF-9EFB-6CDE48ADB3DAQ30830481-8EE2E65C-221C-4D5E-A9D9-112DCC76AD8BQ33443448-4B7291F8-DE31-4B09-B057-52C3544999DEQ33521313-339B3722-3FCD-4984-A545-4C0DA18E6066Q33828855-D640E67F-EAF4-4D69-8F71-15494A157AC9Q34147621-B1D705BA-2CFD-407E-A089-82A45A236BDEQ34487794-70F0230C-D072-4095-A9D8-67E3B46DB221Q34601454-52AF9FB5-B6DB-4BF7-9463-E9B60903753EQ34957256-DB9F7D8D-E0B9-4521-8A0D-834A8EDE5668Q35011376-D6417F74-766D-4C0C-AACD-7CB7B4CB70A1Q35024235-6CFCF93E-91E2-4957-B477-DFB0EBBA8EBDQ35061753-C7E4B83A-8124-4A4C-9A9C-30BA595E955AQ35167861-F6B4C414-8E06-41D3-8318-359E605E67A8Q35249393-343A2DE8-047E-4414-8659-7E71E5B4AE42Q35584016-07075078-191A-4535-A20F-A5728F46DD86Q35641523-96751A72-B0C4-4740-8B09-5AF537DECC13Q35665799-CD7FAC17-F85B-441D-BBA1-FB39DA4F55D2Q35673342-54466197-05F8-45D9-BB57-3FFEA0827275Q35873680-C4DD0308-A80E-4D89-9E4C-3329A1566202Q35988436-FB288E83-60C8-4DF0-84DD-DFA8986B79BDQ36022184-47FADC9B-E354-440C-A150-BED5EAE17E68Q36281345-ED966D12-E9CB-4DEC-81C2-E86FD44B3C89Q36282969-E9268AAA-C59A-4C9C-B9CC-9296E7C99143Q36507795-B68231C2-1E4B-4105-8B0B-1A2AF7700F1AQ37095345-C4B42C90-6C14-4BD4-A397-F8959A976A5FQ37174005-F6671A90-FA4C-4E08-B79C-E17973A270B8Q37356747-46C38E78-6EA0-4362-9E39-E6866945530FQ37402195-2CB5B7EC-B162-4F3D-9570-2C74B974EB13Q37997041-8B4E6750-1771-4750-A76D-2B5CB2FD459AQ37997043-E5060519-22E1-4443-8BF1-B32B71FC331EQ38392178-58E724BA-7503-4E92-B4FC-DEACA1F9EE9B
P50
description
medical researcher
@en
wetenschapper
@nl
name
Silvana Gaudieri
@en
Silvana Gaudieri
@nl
type
label
Silvana Gaudieri
@en
Silvana Gaudieri
@nl
prefLabel
Silvana Gaudieri
@en
Silvana Gaudieri
@nl
P101
P21
P31
P496
0000-0001-6873-0198